ARID1A and cancer: This conjecture was confirmed in a 2015 trial in which Shen et al. found that ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A -mutant tumors [186].